Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (1,932,218)	$ (231,647)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	28,602	21,073
Stock-based compensation	1,822,472	14,764
Loss on equity method investments	53,764	72,621
Loss (gain) on investments	39,981	(3,009)
Non-cash customer consideration	(18,139)	(12,562)
Change in fair value of notes receivable	(269)	1,196
Change in fair value of warrant liabilities	(96,099)	18,482
Gain on deconsolidation of subsidiaries (Note 5)	(31,889)	0
In-process research and development	1,162	0
Loss on disposal of equipment	3,091	0
Other non-cash activity	303	0
Changes in operating assets and liabilities:
Accounts receivable ($4,598 and $(838) from related parties)	20,521	(28,670)
Prepaid expenses and other current assets	8,347	5,565
Inventory	(2,498)	(738)
Other non-current assets	144	(35)
Accounts payable	3,893	(2,771)
Accrued expenses and other current liabilities	(15,637)	29,599
Deferred revenue, current and non-current ($(14,667) and $(9,995) from related parties)	(35,365)	(5,538)
Deferred rent, non-current	2,255	4,320
Other non-current liabilities	82	29,073
Net cash used in operating activities	(147,497)	(88,277)
Cash flows from investing activities:
Purchase of convertible note (related party)	(10,000)	0
Purchases of property and equipment	(26,626)	(51,407)
Purchase of investment in equity securities	(3,691)	(5,000)
Deconsolidation of subsidiaries - cash	(55,721)	0
Business and asset acquisitions, net of cash acquired	(657)	(21,382)
Other	(439)	304
Net cash used in investing activities	(97,134)	(77,485)
Cash flows from financing activities:
Proceeds from reverse recapitalization, net of redemptions of $867,253 and offering costs of $106,838	0	1,510,909
Proceeds from exercise of stock options	120	41
Taxes paid related to net share settlement of equity awards	(981)	0
Repurchase of Founder shares	0	(24,998)
Principal payments on capital leases and lease financing obligation	(1,082)	(764)
Non-controlling interest contributions	0	60,000
Contingent consideration payment	(521)	0
Payment of equity offering issuance costs	(132)	0
Net cash (used in) provided by financing activities	(2,596)	1,545,188
Effect of foreign exchange rates on cash and cash equivalents	(191)	(8)
Net increase (decrease) in cash, cash equivalents and restricted cash	(247,418)	1,379,418
Cash and cash equivalents, beginning of period	1,550,004	380,801
Restricted cash, beginning of period	42,924	5,076
Cash, cash equivalents and restricted cash, beginning of period	1,592,928	385,877
Cash and cash equivalents, end of period	1,302,603	1,739,056
Restricted cash, end of period	42,907	26,239
Cash, cash equivalents, and restricted cash, end of period	1,345,510	1,765,295
Supplemental disclosure of non-cash financing activities:
Purchases of equipment through capital leases	1,268	1,981
Purchases of property and equipment included in accounts payable and accrued expenses	7,959	2,434
Equity received in related parties	8,873	60,054
Convertible financial instruments received for Foundry services	13,689	0
Equity securities and warrants received for Foundry services	3,423	10,000
Lease financing obligation for build-to-suit lease	37,901	0
Common stock issued for business acquisitions	24,607	15,087
Initial fair value of warrant liabilities	0	194,453
Contingent consideration for acquisitions	13,150	0
Deferred offering and acquisitions costs in accounts payable and accrued expense	$ 1,660	$ 1,280